randomized_controlled_trial · 2015
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer X, Astrup A, Fujioka K, et al. · New England Journal of Medicine
highDOI · 10.1056/nejmoa1411892PMID · 26132939Trial · nct01272219Verified
Plain-English summary
Liraglutide produced greater average weight loss and more participants reached clinically meaningful weight-loss thresholds than with placebo.
Population
Adults without type 2 diabetes who had obesity or overweight with dyslipidaemia or hypertension
Sample size
3731
Intervention
Liraglutide 3.0 mg subcutaneously once daily plus diet and exercise versus placebo for 56 weeks
Outcomes measured
Body-weight change|At least 5 percent weight loss|More than 10 percent weight loss|Metabolic measures|Adverse events
Key findings
Liraglutide was associated with greater weight reduction than placebo; nausea and diarrhoea were among the most common adverse events.
Funding & disclosures
Funded by Novo Nordisk; multiple investigators reported financial relationships with the sponsor or other pharmaceutical companies.
Limitations
The study assessed a selected trial population under structured support. Gastrointestinal adverse effects and discontinuation limit generalizability, and longer-term maintenance requires separate evidence.Risk of bias
Low to moderate — randomized and double-blind, with industry sponsorship and sponsor participation.Citation
Pi-Sunyer X, Astrup A, Fujioka K, et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1411892
Linked peptides in the PeptiBrief database